Epoetin alfa biosimilar - NanogenAlternative Names: Nanokine; Recombinant human erythropoietin alfa - Nanogen
Latest Information Update: 04 Mar 2014
At a glance
- Originator Nanogen Biopharmaceutical Co
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Anaemia
Most Recent Events
- 04 Mar 2014 Launched for Anaemia in Vietnam (SC)
- 04 Mar 2014 Launched for Anaemia in Vietnam (IV)